Consensus Repligen Corporation Deutsche Boerse AG

Stocks

RGN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 11:33:00 21/08/2026 am IST			5-day change	1st Jan Change
152.75 ^EUR	+2.17%		+6.30%	+9.77%

30/07	Tranche Update on Repligen Corporation's Equity Buyback Plan announced on June 18, 2008.	CI
30/07	Tranche Update on Repligen Corporation's Equity Buyback Plan announced on December 7, 2023.	CI

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

2fa675a18eee1.bP7W3QNk2fDQAibAu1EGqhoX-Gx8IXLAfzrQZpOs3vI.BdO4lG0yv6-nblL0-ihc_FlwkRpKbyD3CwiVKdXjtaRUrryXWw6zxZZVUQ~39aed8f70c2ade9751eff905d2c7164e

Analysts' recommendations: Repligen Corporation

29/07	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
29/07	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT
29/07	Deutsche Bank Adjusts Repligen Price Target to $200 From $180, Maintains Buy Rating	MT
07/07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
15/05	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
17/04	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
25/02	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
16/01	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
01/25/01	HSBC Initiates Repligen at Buy With $150 Price Target	MT
23/25/23	Repligen Shares Rise After Upgrade From Evercore ISI	MT
22/25/22	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
03/25/03	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
30/25/30	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
29/25/29	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
01/25/01	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
24/25/24	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
30/25/30	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
29/25/29	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
08/25/08	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
18/25/18	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
21/25/21	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
21/25/21	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT
10/25/10	TD Cowen Initiates Repligen at Buy With $200 Price Target	MT
04/25/04	RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating	MT
09/24/09	RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+3.05%
	MEDTRONIC PLC					+5.45%
	CENCORA, INC.					+16.12%
	HOYA CORPORATION					+22.73%
	BECTON, DICKINSON AND COMPANY					+1.26%
	DEXCOM, INC.					+1.93%
	MEDLINE INC.					+30.23%
	WEST PHARMACEUTICAL SERVICES, INC.					+14.63%
	TERUMO CORPORATION					+21.96%
	Average					+13.04%
	Weighted average by Cap.					+8.94%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

181.13USD

Average target price

185.70USD

Spread / Average Target

+2.52%

High Price Target

220.00USD

Spread / Highest target

+21.46%

Low Price Target

145.00USD

Spread / Lowest Target

-19.95%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Deutsche Bank Securities
Benchmark Company
Rothschild & Co Redburn
UBS
HSBC
Evercore ISI
Barclays
Wolfe Research
TD Cowen
Guggenheim
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright